Characterization of Aβ11-40/42 peptide deposition in Alzheimer’s disease and young Down’s syndrome brains: implication of N-terminally truncated Aβ species in the pathogenesis of Alzheimer’s disease
暂无分享,去创建一个
J. Trojanowski | V. Lee | M. Mercken | C. Lemere | Kangning Liu | D. Mann | Ingrid Solano
[1] Rudi D'Hooge,et al. Phenotypic and Biochemical Analyses of BACE1- and BACE2-deficient Mice* , 2005, Journal of Biological Chemistry.
[2] T. Meert,et al. Development of a specific ELISA for the quantitative study of amino-terminally truncated beta-amyloid peptides , 2005, Journal of Neuroscience Methods.
[3] G. Binetti,et al. BACE-2 is overexpressed in Down’s syndrome , 2003, Experimental Neurology.
[4] B. Hyman,et al. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. , 2002, Archives of neurology.
[5] Bruce J Aronow,et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[6] L. Becker,et al. Elevated expression of beta-site amyloid precursor protein cleaving enzyme 2 in brains of patients with Down syndrome , 2002, Neuroscience Letters.
[7] C. Masters,et al. Increased expression of the amyloid precursor β‐secretase in Alzheimer's disease , 2002 .
[8] R. Doms,et al. β-Secretase Processing in the Trans-Golgi Network Preferentially Generates Truncated Amyloid Species That Accumulate in Alzheimer's Disease Brain* , 2002, The Journal of Biological Chemistry.
[9] J. Kornhuber,et al. Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation , 2002, Journal of neurochemistry.
[10] R. Doms,et al. Glu11 site cleavage and N-terminally truncated A beta production upon BACE overexpression. , 2002, Biochemistry.
[11] D. Selkoe,et al. Intraneuronal Aβ42 accumulation in Down syndrome brain , 2002 .
[12] D. Selkoe,et al. Intraneuronal Abeta42 accumulation in Down syndrome brain. , 2002, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[13] C. Masters,et al. Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. , 2002, Annals of neurology.
[14] R. Doms,et al. Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain. , 2002, The Journal of biological chemistry.
[15] E. Rüther,et al. Elevation of β-Amyloid Peptide 2–42 in Sporadic and Familial Alzheimer's Disease and Its Generation in PS1 Knockout Cells* , 2001, The Journal of Biological Chemistry.
[16] S. Younkin,et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation , 2001, Nature Neuroscience.
[17] W. Richards,et al. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation , 2001, Nature Neuroscience.
[18] B. de Strooper,et al. Processing of β-Secretase by Furin and Other Members of the Proprotein Convertase Family* , 2001, The Journal of Biological Chemistry.
[19] V. Dolcini,et al. Identification of Amino-Terminally and Phosphotyrosine-Modified Carboxy-Terminal Fragments of the Amyloid Precursor Protein in Alzheimer's Disease and Down's Syndrome Brain , 2001, Neurobiology of Disease.
[20] Mikio Shoji,et al. Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.
[21] S. Younkin,et al. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[22] H. Cai,et al. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. , 2001, Nature neuroscience.
[23] W. Richards,et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. , 2001, Nature neuroscience.
[24] T. L. Tekirian. Commentary: Abeta N- Terminal Isoforms: Critical contributors in the course of AD pathophysiology. , 2001, Journal of Alzheimer's disease : JAD.
[25] V. Dolcini,et al. Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain. , 2001, Neurobiology of disease.
[26] C. Schnitzler,et al. BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein , 2000 .
[27] M. Citron,et al. Expression Analysis of BACE2 in Brain and Peripheral Tissues* , 2000, The Journal of Biological Chemistry.
[28] F. Acquati,et al. The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the Down critical region , 2000, FEBS letters.
[29] C. Southan,et al. ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site. , 2000, Molecular and cellular neurosciences.
[30] C. Schnitzler,et al. BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[31] Alfredo G. Tomasselli,et al. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.
[32] J. Treanor,et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.
[33] J. Trojanowski,et al. Quantification of Modified Amyloid β Peptides in Alzheimer Disease and Down Syndrome Brains , 1998, Journal of neuropathology and experimental neurology.
[34] Y. Sakaki,et al. Presenilin 1 Mutations Linked to Familial Alzheimer's Disease Increase the Intracellular Levels of Amyloid β‐Protein 1–42 and Its N‐Terminally Truncated Variant(s) Which Are Generated at Distinct Sites , 1998, Journal of neurochemistry.
[35] M. Raskind,et al. Early Amyloid Deposition in the Medial Temporal Lobe of Young Down Syndrome Patients: A Regional Quantitative Analysis , 1998, Experimental Neurology.
[36] M. Emmerling,et al. Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. , 1997, Biochemical and biophysical research communications.
[37] J. Trojanowski,et al. Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. , 1996, The American journal of pathology.
[38] D. Selkoe,et al. Sequence of Deposition of Heterogeneous Amyloid β-Peptides and APO E in Down Syndrome: Implications for Initial Events in Amyloid Plaque Formation , 1996, Neurobiology of Disease.
[39] D. Mann,et al. Presence of soluble amyloid β–peptide precedes amyloid plaque formation in Down's syndrome , 1996, Nature Medicine.
[40] Carl W. Cotman,et al. Amino-terminal Deletions Enhance Aggregation of β-Amyloid Peptides in Vitro(*) , 1995, The Journal of Biological Chemistry.
[41] D. Mann,et al. Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in down Syndrome , 1995, Annals of neurology.
[42] D. Mann,et al. Dominant and differential deposition of distinct β-amyloid peptide species, Aβ N3(pE), in senile plaques , 1995, Neuron.
[43] D. Mann,et al. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. , 1995, Neuron.
[44] C. Cotman,et al. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. , 1995, The Journal of biological chemistry.
[45] P. Greengard,et al. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[46] P. Lansbury,et al. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. , 1993, Biochemistry.